| Literature DB >> 33402667 |
Muhammad Aslam1, Nirosiya Kandasamy2, Anwar Ullah2,3,4, Nagarajan Paramasivam5, Mehmet Ali Öztürk6,7, Saima Naureen2,8, Abida Arshad8, Mazhar Badshah9, Kafaitullah Khan10, Muhammad Wajid11, Rashda Abbasi3, Muhammad Ilyas12, Roland Eils13,14, Matthias Schlesner15, Rebecca C Wade6,16, Nafees Ahmad3, Jakob von Engelhardt17.
Abstract
Rare variants in the beta-glucocerebrosidase gene (GBA1) are common genetic risk factors for alpha synucleinopathy, which often manifests clinically as GBA-associated Parkinson's disease (GBA-PD). Clinically, GBA-PD closely mimics idiopathic PD, but it may present at a younger age and often aggregates in families. Most carriers of GBA variants are, however, asymptomatic. Moreover, symptomatic PD patients without GBA variant have been reported in families with seemingly GBA-PD. These observations obscure the link between GBA variants and PD pathogenesis and point towards a role for unidentified additional genetic and/or environmental risk factors or second hits in GBA-PD. In this study, we explored whether rare genetic variants may be additional risk factors for PD in two families segregating the PD-associated GBA1 variants c.115+1G>A (ClinVar ID: 93445) and p.L444P (ClinVar ID: 4288). Our analysis identified rare genetic variants of the HSP70 co-chaperone DnaJ homolog subfamily B member 6 (DNAJB6) and lysosomal protein prosaposin (PSAP) as additional factors possibly influencing PD risk in the two families. In comparison to the wild-type proteins, variant DNAJB6 and PSAP proteins show altered functions in the context of cellular alpha-synuclein homeostasis when expressed in reporter cells. Furthermore, the segregation pattern of the rare variants in the genes encoding DNAJB6 and PSAP indicated a possible association with PD in the respective families. The occurrence of second hits or additional PD cosegregating rare variants has important implications for genetic counseling in PD families with GBA1 variant carriers and for the selection of PD patients for GBA targeted treatments.Entities:
Year: 2021 PMID: 33402667 PMCID: PMC7785741 DOI: 10.1038/s41525-020-00163-8
Source DB: PubMed Journal: NPJ Genom Med ISSN: 2056-7944 Impact factor: 8.617